MacroGenics Inc Plunges 73% After Interim Data from TAMARACK Study Shows Fatal Outcomes
Washington, D.C. – MacroGenics Inc (NASDAQ: MGNX) faced a significant setback as shares plummeted over 50% following the release of interim data from the TAMARACK Phase 2 study. The study focused on vobramitamab duocarmazine (vobra duo), a treatment targeting B7-H3 in metastatic castration-resistant prostate cancer (mCRPC) patients. As of April 12, 2024, the company reported a high rate of adverse events, including five deaths during the trial and over 50% rate of grade 3 or …